• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项使用极低热量配方饮食的马吲哚双盲试验。

A double-blind trial of mazindol using a very low calorie formula diet.

作者信息

Baird I M, Howard A N

出版信息

Int J Obes. 1977;1(3):271-8.

PMID:363631
Abstract

Thirty-eight obese patients, resistant to conventional diet therapy, agreed to consume a 1.09 MJ (260 kcal)/day semi-synthetic diet consisting of 25 g egg albumin, 40 g oligosaccharides, vitamins and minerals, and were seen weekly as outpatients for eight weeks. At the beginning, the semi-synthetic diet was given with either the anorectic drug, mazindol (2 mg/day) or a placebo for four weeks and then changed over for the remaining four weeks; the study being conducted on a double-blind basis. The final treatment was a 4.2 MJ (1000 KCAL) conventional diet for a further four weeks without drug or placebo. Twenty-five patients completed the first eight weeks and 21 patients the final four weeks of the trial. The total mean weight losses were as follows: week 4, 9.3 kg; week 8, 13.7 kg; week 12, 12.2 kg. There was no significant difference in weight loss between mazindol treatment and placebo but the former group reported feeling less hungry. The chief side-effects observed were dizziness, nausea, dry mouth, insomnia and depression which were more frequent with mazindol. Six patients had to stop mazindol because of side-effects, but were able to continue the diet alone. It is concluded that a semi-synthetic diet containing 1.09 MJ (260 kcal) daily can be successfully employed in the treatment of obese outpatients, and is a practical therapeutic alternative to admission to hospital. There is no clinical advantage to be gained by the additional use of the anorectic drug, mazindol.

摘要

38名对传统饮食疗法有抵抗性的肥胖患者同意食用一种每天1.09兆焦耳(260千卡)的半合成饮食,该饮食由25克蛋清、40克低聚糖、维生素和矿物质组成,并且作为门诊病人每周接受观察,为期8周。开始时,半合成饮食与食欲抑制剂马吲哚(2毫克/天)或安慰剂搭配服用4周,然后在接下来的4周进行更换;该研究采用双盲方式进行。最后4周的治疗是一种4.2兆焦耳(1000千卡)的传统饮食,不服用药物或安慰剂。25名患者完成了试验的前8周,21名患者完成了试验的最后4周。总体平均体重减轻情况如下:第4周,9.3千克;第8周,13.7千克;第12周,12.2千克。马吲哚治疗组和安慰剂组在体重减轻方面没有显著差异,但前一组报告饥饿感较轻。观察到的主要副作用是头晕、恶心、口干、失眠和抑郁,这些在马吲哚组中更常见。6名患者因副作用不得不停止服用马吲哚,但能够继续单独饮食。结论是,一种每天含有1.09兆焦耳(260千卡)的半合成饮食可成功用于治疗肥胖门诊病人,是一种切实可行的替代住院治疗的方法。额外使用食欲抑制剂马吲哚没有临床益处。

相似文献

1
A double-blind trial of mazindol using a very low calorie formula diet.一项使用极低热量配方饮食的马吲哚双盲试验。
Int J Obes. 1977;1(3):271-8.
2
AN 448 Sandoz (Mazindol) in the treatment of obesity.山德士公司的AN 448(马吲哚)用于治疗肥胖症。
Med J Aust. 1976 Mar 13;1(11):343-5.
3
Treatment of obesity: comparison of physician and nonphysician therapists using placebo and anorectic drugs in a double-blind trial.肥胖症的治疗:在一项双盲试验中比较使用安慰剂和厌食药的医生与非医生治疗师。
Int J Obes. 1977;1(2):113-20.
4
[Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)].饮食、马吲哚与安慰剂治疗外源性肥胖效果的比较试验(作者译)
Med Klin. 1976 Nov 12;71(46):2013-6.
5
Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients.
Diabete Metab. 1978 Sep;4(3):193-9.
6
Usefulness of mazindol in combined diet therapy consisting of a low-calorie diet and Optifast in severely obese women.马吲哚在严重肥胖女性采用低热量饮食和全安素组成的联合饮食疗法中的效用。
Int J Clin Pharmacol Res. 1994;14(4):125-32.
7
The treatment of obesity with a very-low-calorie liquid-formula diet: an inpatient/outpatient comparison using skimmed-milk protein as the chief protein source.
Int J Obes. 1978;2(3):321-32.
8
[Long-term treatment of patients with obesity using mazindol and a reducing diet].
Ned Tijdschr Geneeskd. 1982 May 29;126(22):990-4.
9
Double-blind clinical evaluation of mazindol (42-548) in obese diabetics.
Curr Ther Res Clin Exp. 1975 Dec;18(6):816-24.
10
A multicentre study comparing mazindol and placebo in obese patients.一项在肥胖患者中比较马吲哚与安慰剂的多中心研究。
J Int Med Res. 1977;5(2):85-90. doi: 10.1177/030006057700500202.

引用本文的文献

1
Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.安非拉酮和马吲哚作为单一疗法治疗肥胖或超重患者的疗效和安全性的系统评价与荟萃分析。
Clinics (Sao Paulo). 2017 May;72(5):317-324. doi: 10.6061/clinics/2017(05)10.
2
Multidisciplinary treatment of obesity with a protein-sparing modified fast: results in 668 outpatients.采用保留蛋白质的改良禁食法对肥胖症进行多学科治疗:668例门诊患者的治疗结果
Am J Public Health. 1985 Oct;75(10):1190-4. doi: 10.2105/ajph.75.10.1190.